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Introduction: This randomized phase II trial evaluated single-agent
pemetrexed or sequential pemetrexed/gemcitabine in patients with non-
small cell lung cancer (NSCLC) who were elderly (70 years) or
younger than 70 years and ineligible for platinum-based chemotherapy.
Methods: Chemonaive patients with stage IIIB/IV NSCLC and an
Eastern Cooperative Oncology Group performance status of 0 to 2
received either 500 mg/m2 of pemetrexed (day 1, every 3 weeks) for
eight cycles, or the same dosage of pemetrexed for cycles 1 and 2
and then 1200 mg/m2 of gemcitabine (days 1 and 8, every 3 weeks)
for cycles 3 and 4 (repeated once for a total of eight cycles). All
patients were given vitamin B12 and folic acid supplementation.
Results: From July 2003 to July 2004, 87 patients (44 pemetrexed; 43
pemetrexed/gemcitabine) received treatment. The median time to pro-
gression was 4.5 (95% confidence interval: 3.0–9.3) and 4.1 months
(95% confidence interval: 1.7–5.8) for the pemetrexed and pemetrexed/
gemcitabine arms, respectively, and the median progression-free sur-
vival time was 3.3 months for both arms. Tumor response rates for the
pemetrexed and pemetrexed/gemcitabine arms were 4.5% and 11.6%,
respectively. The median overall survival time was 4.7 months for the
pemetrexed arm and 5.4 months for the pemetrexed/gemcitabine arm,
with respective 1-year survival rates of 28.5% and 28.1%. Grade 3/4
hematologic toxicity consisted of neutropenia (4.5% pemetrexed; 2.3%
pemetrexed/gemcitabine), febrile neutropenia (4.5% pemetrexed;
4.7% pemetrexed/gemcitabine), thrombocytopenia (4.5% pem-
etrexed; 7.0% pemetrexed/gemcitabine), and anemia (6.8% pem-
etrexed; 4.7% pemetrexed/gemcitabine). No grade 3/4 nonhema-
tologic toxicities exceeded 4.7% in either arm.
Conclusions: Single-agent pemetrexed and sequential pemetrexed/
gemcitabine have shown moderate activity and are well tolerated as
first-line treatments for advanced NSCLC in elderly patients or
patients unsuitable for platinum-based combination chemotherapy.
Key Words: Advanced NSCLC, Elderly patients, PS 2 patients,
Pemetrexed, Gemcitabine.
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Non-small cell lung cancer (NSCLC) represents approxi-mately 80% to 87% of all lung cancers.1 Because the
majority of patients present with metastatic NSCLC, pallia-
tive treatment is often the only therapeutic option.
Platinum-based combination chemotherapy is currently
the standard treatment for patients with advanced NSCLC.
However, two categories of patients, the elderly and patients
with poor performance status (PS; 2), are often not candi-
dates for platinum-based combinations because of poor gen-
eral conditions and comorbidities.
More than 50% of advanced NSCLC cases are diag-
nosed in patients older than 65 years, and approximately 30%
to 40% of cases are diagnosed in patients older than 70
years,2,3 yet disproportionately low numbers of elderly par-
ticipants are included in clinical trials.4–7 Three phase III
trials constitute the published evidence-based literature for
the elderly.8–10 Chemotherapy treatment in the elderly is
complicated by a number of age-related issues. Decreased
hepatic, renal, and bone marrow functions increase toxicity,
particularly cisplatin-related toxicity.7,8 Furthermore, comor-
bid diseases, which may significantly affect functional
status, general health, and tumor symptoms, are frequently
present.11,12 Because of these complications, single-agent
chemotherapy is often the recommended treatment, even by
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American Society of Clinical Oncology guidelines, for el-
derly patients with advanced NSCLC.6,8,10,13,14 The findings
of the two phase III trials that compared single-agent versus
combination therapy in the elderly8,9 produced different con-
clusions: the Multicenter Italian Lung Cancer in the Elderly
Study showed that the combination of gemcitabine and vi-
norelbine was not more effective or tolerable than either
agent alone, whereas the Southern Italy Cooperative Oncol-
ogy Group found that the combination of gemcitabine and
vinorelbine was associated with significantly better overall
survival than vinorelbine alone. Nevertheless, the difference
in sample sizes between the two trials (698 versus 120
patients for the Multicenter Italian Lung Cancer in the Elderly
Study and the Southern Italy Cooperative Oncology Group
trial, respectively) should be noted.
The proportion of patients with PS 2 enrolled in clinical
trials is often less than 20% of the whole study population,
even though the proportion of PS 2 patients is consistently
higher in population-based studies.15 For these patients, no
treatment is widely accepted as standard. A subgroup analysis
of several randomized trials16 suggests that several new-
generation cytotoxic drugs (gemcitabine, vinorelbine, and
taxanes) are superior to supportive care in this patient cate-
gory. Therefore, single-agent chemotherapy with these drugs
may be the preferred option for palliative treatment of PS 2
patients.13,16–18
Pemetrexed, a novel multitargeted antifolate, inhibits
three enzymes involved in pyrimidine and purine synthesis:
thymidylate synthase, dihydrofolate reductase, and glyci-
namide ribonucleotide formyl transferase.19 Pemetrexed has
shown activity as a single agent in several phase II trials and
one phase III trial in patients with NSCLC.20–23 Supplemen-
tation with folic acid and vitamin B12, which is required to
reduce pemetrexed toxicity,24 results in a mild toxicity profile
that allows for drug evaluation in the elderly.
Gemcitabine, a cytosine–arabinoside analogue, acts by
upsetting deoxynucleotide pools and interfering with DNA
chain elongation.25 Gemcitabine has previously shown good
activity and tolerability in advanced NSCLC elderly patients
in phase II trials26–30 and in a phase III study.8
We conducted a multicenter phase II randomized trial
to evaluate the time to progressive disease (TtPD) of single-
agent pemetrexed or sequential pemetrexed/gemcitabine as
first-line therapy in elderly patients or in patients with
NSCLC who were ineligible for platinum-based chemother-
apy. Sequential treatment with single-agent pemetrexed and
then single-agent gemcitabine was chosen in an effort to
maximize the activity of both drugs while producing a lower
toxicity profile than that seen with the combination.31 Sec-
ondary objectives included toxicity, response rate, and overall
survival.
MATERIALS AND METHODS
Eligibility Criteria
Patients with histological or cytological confirmation of
stage IIIB NSCLC (with supraclavicular lymph node metas-
tases or pleural effusion) or stage IV NSCLC not amenable to
surgery or curative radiotherapy were eligible for the study.
Additionally, eligible patients met the following criteria: no
prior chemotherapy (prior surgery and radiotherapy were
permitted as long as relapse or disease progression had
occurred after the procedure or therapy); measurable disease
according to Response Evaluation Criteria in Solid Tumors
criteria32; age70 years or70 years for patients who, in the
investigator’s opinion, were ineligible for platinum-based
chemotherapy because of poor PS or comorbidities; an East-
ern Cooperative Oncology Group PS of 0 to 2; an estimated
life expectancy of at least 12 weeks; and adequate bone
marrow, renal, and hepatic function. Patients with symptom-
atic brain metastases were ineligible for the study (whereas
patients with a history of brain metastases were permitted to
participate in the study), as were patients with an inability to
interrupt nonsteroidal antiinflammatory drugs (2 days before,
the day of, and 2 days after receiving pemetrexed), uncon-
trolled pleural effusions, or inability or unwillingness to take
steroids or vitamin supplementation. The protocol was ap-
proved through institutional ethical review boards, and all
patients provided written informed consent before treatment.
The study was conducted in accordance with the ethical
principles in the Declaration of Helsinki and good clinical
practice.
Study Design and Sample Size
This open-label phase II study was designed to ran-
domly assign 90 patients to one of two regimens (single-agent
pemetrexed or single-agent pemetrexed followed sequentially
by single-agent gemcitabine), and the trial was not considered
complete until at least 73 patients progressed. This sample
size was chosen on the basis of a selection design using the
primary endpoint of TtPD. The selection design assumed that
the primary goal of the trial was to select a regimen for a
larger phase III trial. Type I error, or alpha error, was not
controlled under this design. The treatment that was observed
to have a numerically longer TtPD and a better observed
tolerability was to be selected as the best choice for subse-
quent studies. Assuming a hazard ratio of 0.82, there was at
least an 80% chance of correctly selecting the preferred
regimen. Assuming a 5-month median TtPD in the inferior
arm, this design required a 9-month follow-up period after the
last patient was enrolled.
Randomization was controlled by a computerized voice
response unit at a central location for all study sites and was
stratified according to disease stage (stage IIIB versus stage
IV) and PS (0–1 versus 2).
Treatment Plan
Eligible patients were randomly assigned either to re-
ceive 500 mg/m2 of pemetrexed as a 10-minute intravenous
infusion on day 1 every 3 weeks for a maximum of eight
cycles, or pemetrexed at the same dosage for cycles 1 and 2
and then 1200 mg/m2 of gemcitabine as a 30-minute intra-
venous infusion on days 1 and 8 every 3 weeks for cycles 3
and 4. This four-cycle schedule was repeated once, for a total
of eight cycles.
All patients were instructed to take 350 to 1000 g of
folic acid orally each day, beginning approximately 1 to 2
weeks before the first dose of pemetrexed and continuing
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daily until 3 weeks after the last dose of pemetrexed. A
1000-g vitamin B12 injection was administered intramuscu-
larly approximately 1 to 2 weeks before the first dose of
pemetrexed and was repeated approximately every 9 weeks
until 3 weeks after the last dose of pemetrexed. Patients
treated with pemetrexed were instructed to take dexametha-
sone (4 mg orally, twice daily, on the day before, the day of,
and the day after pemetrexed) as a prophylactic measure
against skin rash.
Patients received full supportive care. Granulocyte col-
ony–stimulating factor support was allowed for prolonged
myelosuppression and febrile neutropenia. Leucovorin was
allowed for common toxicity criteria grade 4 leukopenia
lasting longer than 3 days, grade 4 neutropenia lasting longer
than 3 days, grade 4 thrombocytopenia, bleeding associated
with grade 3 thrombocytopenia, or grade 3 or 4 mucositis.
The day 8 dose of gemcitabine was reduced by 25% for
an absolute neutrophil count (ANC) of 0.5 to 1.0  109/liter
or a platelet count of 50 to 100  109/liter, and this dose was
omitted for an ANC 0.5  109/liter or a platelet count
50  109/liter. The day 8 dose of gemcitabine was reduced
by 50% or was omitted for grade 3 nonhematologic toxicity
(except nausea and vomiting) and was omitted for grade 4
nonhematologic toxicity. Omitted doses were not admin-
istered later, and patients who required a dose reduction
continued to receive the reduced dose for the remainder of
the study.
Subsequent cycles were delayed because of toxicity
(ANC 1.5  109/liter, platelets 100  109/liter, a calcu-
lated creatinine clearance 45 ml/min, or nonhematologic
toxicity above grade 1 or baseline) for a maximum of 3
weeks, after which the patient was discontinued from the
study. Doses of both drugs in subsequent cycles were reduced
by 25% of the previous dose for platelet counts 50 
109/liter and/or ANC 0.5  109/liter, or for diarrhea of
grade 3 or higher observed in the previous cycle. Pemetrexed
was reduced by 50% of the previous dose for grade 3 or 4
mucositis. For other nonhematologic toxicities of at least
grade 3, doses were reduced to 75% of the previous dose if
deemed appropriate by the treating physician. Patients were
discontinued from the study if there was a recurrence of grade
3 or 4 thrombocytopenia, neutropenia, or mucositis after two
dose reductions.
Baseline and Treatment Assessments
No more than 4 weeks before enrollment, patients were
assessed by chest and abdominal computed tomography
scans, magnetic resonance imaging or computed tomography
scan of the brain, bone scan, and chest x-ray (ultrasound was
not permitted). No more than 1 week before enrollment,
patients were assessed by a history and physical examination,
tumor measurement of palpable lesions, hematology, com-
plete blood chemistries, calculated creatinine clearance, elec-
trocardiogram, evaluation of PS, and a comorbidities assess-
ment using the Charlson comorbidity index,33 a 19-item
measure of health status by which the rater identifies the
presence or absence of each disease state, which has a
corresponding numeric value; the values for all present dis-
ease states are summed, with a higher score corresponding to
a higher degree of comorbidity. During therapy, laboratory
assessments included hematology, blood chemistries, and
calculated creatinine clearance. After the second and fourth
cycles of chemotherapy, and then every two cycles thereafter,
radiologic tumor assessment was performed by the same
method that had been used at baseline. Tumor response was
assessed using the Response Evaluation Criteria in Solid
Tumors criteria32 and required confirmation 3 to 4 weeks
after initial response. Toxicity evaluations, performed at the
end of each cycle, were based on the National Cancer Insti-
tute common toxicity criteria, version 2.34
All patients who received at least one dose of a study
drug were assessed for TtPD, progression-free survival
(PFS), survival, response, and toxicity.
Statistical Considerations
TtPD was defined as the time from the date of random-
ization to the first date of documented disease progression
and was censored on the date of last tumor assessment for
patients without documented progressive disease at the time
of analysis. Because many patients died without documented
progressive disease, there was a high rate of censoring for
TtPD. Therefore, PFS was added retrospectively as a similar
measure that would have less censoring. PFS was defined as
the time from the date of randomization to the first date of
documented disease progression or death from any cause and
was censored on the date of last follow-up for patients not
known to have died at the time of the analysis. Overall
survival was defined as the time from the date of randomiza-
tion to the date of death from any cause and was censored on
the date of last follow-up for patients not known to have died
at the time of analysis.
The Kaplan–Meier method35 was used to estimate pa-
rameters for TtPD, PFS, and overall survival (OS), and the
log-rank test was used for comparison of these measures
between treatment arms. Interval estimates were calculated
using 95% confidence intervals (CI). The tumor response
rate, including a 95% CI, was reported.36
Cox regression analyses were used to examine any
possible relationships between efficacy (TtPD, PFS, and OS)
and the Charlson comorbidity index. Because of the small
sample size, these analyses were considered exploratory.
RESULTS
Patient Characteristics
From July 2003 through July 2004, 92 patients were
randomly assigned to receive either pemetrexed (47 patients)
or sequential pemetrexed/gemcitabine therapy (45 patients).
Of the 92 randomized patients, 87 patients received study
therapy, 44 in the pemetrexed arm and 43 in the sequential
pemetrexed/gemcitabine arm. Of the 47 patients randomly
assigned to pemetrexed, three patients received no treatment:
one because of unmet protocol entry criteria, one because of
worsening of PS, and one because of the patient’s decision.
Of the 45 patients randomly assigned to sequential pem-
etrexed/gemcitabine, one patient received no treatment be-
cause of unmet protocol entry criteria, and one patient was
discontinued immediately after receiving gemcitabine instead
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of pemetrexed in the first cycle (this patient was not consid-
ered to have received study therapy and was excluded from
further analysis).
Baseline patient and disease characteristics for all
treated patients are listed in Table 1. The two arms were well
balanced for all demographic and stratification factors. All 87
patients were evaluable for efficacy and toxicity, and clinical
data were collected up to March 14, 2005.
Treatment Administration
Eighty-seven patients received at least one cycle of
therapy, 40 patients (21 pemetrexed and 19 pemetrexed/
gemcitabine) received at least four cycles, and 26 patients (13
per arm) received at least six cycles of therapy. The total
number of cycles administered was 163 for pemetrexed and
166 for sequential pemetrexed/gemcitabine, with a median
number of 2.5 cycles for pemetrexed and 3.0 cycles for
sequential pemetrexed/gemcitabine (range, 1–8 for both
arms). The actual median dose intensity was 164.8 mg/m2 per
week (range, 95.0–169.5) for the pemetrexed arm and 166.7
mg/m2 per week (pemetrexed; range, 142.6–171.2) and 786.7
mg/m2 per week (gemcitabine; range, 384.7–839.3) for the
sequential pemetrexed/gemcitabine arm. Patients received
94.9% of the planned dose intensity in the pemetrexed arm
and 98.3% (pemetrexed) and 90.8% (gemcitabine) of the
planned dose intensity in the sequential pemetrexed/gemcit-
abine arm.
A total of 36 and 33 dose delays occurred in the
pemetrexed and sequential pemetrexed/gemcitabine arms, re-
spectively; most of these delays were caused by scheduling
conflicts (75% pemetrexed and 73% sequential pemetrexed/
gemcitabine). There were only seven dose reductions (five in
the pemetrexed arm and two in the sequential pemetrexed/
gemcitabine arm). In the pemetrexed arm, reasons for dose
reductions were febrile neutropenia (two), neutropenia (two),
and thrombocytopenia (one).
Efficacy
The median TtPD was similar in both arms: 4.5 months
(95% CI: 3.0–9.3) and 4.1 months (95% CI: 1.7–5.8) for
pemetrexed and sequential pemetrexed/gemcitabine, respec-
tively (Figure 1). A high rate of censoring occurred for TtPD
(15 patients had no objective PD), mainly in the pemetrexed
arm for 12 patients because of a lack of documented disease
progression. Of the 12 patients in the pemetrexed arm without
documented disease progression, four died either on study or
during the first follow-up visit (three from progression and
one from non–drug-related respiratory failure). Of the re-
maining eight patients, five discontinued early (during visit 1
or 2), and no imaging assessments of disease status were done
after discontinuation from the study drug.
Because of the unexpectedly high rate of censoring for
TtPD, PFS also was analyzed. Because PFS included death as
an event, the rate of censoring for PFS was much lower than
the rate of censoring for TtPD: 44 of 87 patients had censored
times for TtPD, whereas only 14 of 87 patients had censored
times for PFS. The median PFS time was 3.3 (months) for
both the pemetrexed (95% CI: 2.0–4.4) and the sequential
pemetrexed/gemcitabine (95% CI: 1.7–4.1) arms (Figure 2).
Table 2 shows best overall response. Response could
not be assessed in 17 (38.6%) patients in the pemetrexed arm
and in four (9.3%) patients in the sequential pemetrexed/
gemcitabine arm. In the majority of the cases, this was due to
a lack of follow-up tumor assessments attributable to early
discontinuations: 17 of 21 patients with unassessable re-
sponses discontinued in visits 1 or 2, and of these 17, seven
died on study (four from progression and three from serious
adverse events considered unrelated to the study drug). In the
pemetrexed arm, early discontinuations of patients leading to
nonassessable responses were attributable to lack of efficacy
(in two patients), death (in three patients from progression
and in two patients from serious adverse events considered
unrelated to the study drug), adverse events (unrelated to the
study drug in four patients and related in two patients), and
TABLE 1. Baseline Patient and Disease Characteristics
No. of Patients (%)
Pem
(n  44)
Sequential
Pem/Gem
(n  43)
Sex
Male 35 (79.5) 29 (67.4)
Female 9 (20.5) 14 (32.6)
Age (yr)
Median 73 73
Range 58–82 61–83
70 35 (79.5) 34 (79.1)
70 9 (20.5) 9 (20.9)
ECOG performance status
0 4 (9.1) 3 (7.0)
1 26 (59.1) 23 (53.5)
2 14 (31.8) 17 (39.5)
Stage of disease
IIIB 8 (18.2) 8 (18.6)
IV 36 (81.8) 35 (81.4)
Histology
Adenocarcinoma 18 (40.9) 24 (55.8)
Squamous 11 (25.0) 15 (34.9)
Large cell 7 (15.9) 3 (7.0)
Mixed 1 (2.3) 0 (0.0)
Undefined NSCLC 7 (15.9) 1 (2.3)
Number of disease sites
1–3 24 (54.6) 27 (62.8)
4–6 18 (40.9) 15 (34.9)
6 2 (4.5) 1 (2.3)
Number of comorbidities
None 18 (40.8) 11 (25.6)
1 14 (31.8) 20 (46.5)
2 5 (11.4) 7 (16.3)
3 5 (11.4) 5 (11.6)
4 1 (2.3) 0 (0)
Unknown 1 (2.3) 0 (0)
Pem, pemetrexed; pem/gem, pemetrexed/gemcitabine; ECOG, Eastern Cooperative
Oncology Group; NSCLC, non-small cell lung cancer.
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other causes (in one patient); in the sequential pemetrexed/
gemcitabine arm, early discontinuations were attributable to
death (one from an adverse event considered unrelated to the
study drug and one from progression) and adverse events
(related to the study drug in one patient). Objective tumor
responses were reported in two (4.5%) patients in the pem-
etrexed arm (95% CI: 0.6–15.5) and in five (11.6%) patients
in the sequential pemetrexed/gemcitabine arm (95% CI: 3.9–
25.1). The rates of stable disease were 34.1% and 23.3% for
pemetrexed and sequential pemetrexed/gemcitabine arms, re-
spectively, resulting in overall disease control (response stable
disease) in 17 (38.6%) and 15 (34.9%) patients. Additionally,
there were four unconfirmed responses (restaging not completed
after 1 month, per protocol), three in the pemetrexed arm and
FIGURE 1. Kaplan–Meier time to progressive disease.
FIGURE 2. Kaplan–Meier progression-free survival.
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one in the sequential pemetrexed/gemcitabine arm for response
rates of 11.4% and 14.0%, respectively.
The median overall survival time was 4.7 months (95%
CI: 3.2–6.8) for pemetrexed and 5.4 months (95% CI: 3.8–
7.6) for sequential pemetrexed/gemcitabine (Figure 3). The
1-year survival rate was 28.5% (95% CI: 14.0–43.1) and
28.1% (95% CI: 13.2–42.9) for pemetrexed and sequential
pemetrexed/gemcitabine, respectively.
As an exploratory analysis, we also examined efficacy
outcomes within the PS 0/1 and PS 2 subgroups. Thirty
patients in the pemetrexed arm and 26 patients in the sequen-
tial pemetrexed/gemcitabine arm had a PS of 0 or 1. The
median PFS time was 4.4 months for pemetrexed and 3.7
months for sequential pemetrexed/gemcitabine, and the me-
dian OS time was 5.2 months for pemetrexed and 7.6 months
for sequential pemetrexed/gemcitabine. Fourteen patients in
the pemetrexed arm and 17 patients in the sequential pem-
etrexed/gemcitabine arm had a PS of 2. The median PFS time
was 1.3 months for pemetrexed and 1.9 months for sequential
pemetrexed/gemcitabine, and the median OS time was 1.8
months for pemetrexed and 3.9 months for sequential pem-
etrexed/gemcitabine. There were no statistically significant
differences between treatment arms within the PS 0/1 or PS
2 subgroups.
Per the Charlson Comorbidity Index, approximately
74% of patients had either no or one comorbidity at baseline,
indicating a fairly low rate of comorbidity in this study. Of
the 19 items, only the presence of diabetes and/or moderate to
severe liver disease was suggested by the Cox models to be
associated with an increased risk of death.
Toxicity
Hematologic toxicity was mild (Table 3). Grade 3 and
4 toxicities were neutropenia, febrile neutropenia, thrombo-
TABLE 2. Best Overall Response
Response
No. of Patients (%)
Pem
(n  44)
Sequential Pem/Gem
(n  43)
Overall response 2 (4.5) 5 (11.6)
(95% CI) (0.6–15.5) (3.9–25.1)
Complete response 0 (0) 0 (0)
Partial response 2 (4.5) 5 (11.6)
Stable disease 15 (34.1) 10 (23.3)
Progressive disease 10 (22.7) 24 (55.8)
Not assessable/unknown 17 (38.6) 4 (9.3)
Pem, pemetrexed; pem/gem, pemetrexed/gemcitabine; CI, confidence interval.
FIGURE 3. Kaplan–Meier overall survival.
TABLE 3. Worst Grade 3/4 NCI-CTC Hematologic Toxicity
Toxicity
No. of Patients (%)
Pem
(n  44)
Sequential
Pem/Gem
(n 43)
G3 G4 G3 G4
Neutropenia 1 (2.3) 1 (2.3) 1 (2.3) 0 (0)
Febrile neutropenia 2 (4.5) 0 (0) 2 (4.7) 0 (0)
Anemia 2 (4.5) 1 (2.3) 2 (4.7) 0 (0)
Thrombocytopenia 1 (2.3) 1 (2.3) 3 (7.0) 0 (0)
NCI-CTC, National Cancer Institute common toxicity criteria; Pem, pemetrexed;
pem/gem, pemetrexed/gemcitabine; G, grade.
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cytopenia, and anemia. In the sequential pemetrexed/gemcit-
abine arm, no grade 4 toxicities occurred.
Nonhematologic toxicities were mild, with each grade
3/4 toxicity occurring in no more than two patients in both
arms (Table 4). Allergic reaction, diarrhea, melena, mucosi-
tis, pulmonary, edema, increased alanine aminotransferase,
and anorexia were reported in the pemetrexed arm, whereas
fatigue, rash, and abdominal pain were reported in the se-
quential pemetrexed/gemcitabine arm.
Discontinuations attributable to treatment-related ad-
verse events occurred in four patients in the pemetrexed arm
(because of pneumonia, maculopapular rash, exanthema, and
neutropenia) and two patients in the sequential pemetrexed/
gemcitabine arm (because of abdominal pain and allergic
dermatitis). Twelve deaths occurred during the study, none of
which were related to a study drug. Eight deaths were disease
related, and four deaths were attributable to serious adverse
events.
DISCUSSION
In this phase II randomized trial of elderly patients (age
70 years) and patients younger than 70 years who were
unsuitable for platinum-based chemotherapy (with a PS of 2),
single-agent pemetrexed and sequentially applied pem-
etrexed/gemcitabine were effective and well tolerated as
first-line treatments of advanced NSCLC. For the pemetrexed
and sequential pemetrexed/gemcitabine arms, respectively,
the median TtPD was 4.5 months and 4.1 months, and the
median overall survival time was 4.7 months and 5.4 months.
The median PFS time, which was analyzed because of an
unexpectedly high rate of censoring for TtPD, was 3.3
months for each treatment arm. Objective tumor responses
were reported in two patients treated with pemetrexed and in
five patients treated with sequential pemetrexed/gemcitabine.
Hematologic and nonhematologic toxicities were mild, with
no grade 4 hematologic toxicities seen in the sequential
pemetrexed/gemcitabine arm and with no more than two
patients with grade 3/4 nonhematologic toxicities seen in
both arms.
Single-agent pemetrexed as both first-line and second-
line treatment of advanced NSCLC has yielded encouraging
response rates and survival and a good toxicity profile when
administered with adequate vitamin supplementation.20–24 In
two phase II studies, 600 mg/m2 of pemetrexed was admin-
istered to chemonaive patients with advanced NSCLC.20,21
The objective response rates were 15.8% and 23.3%, respec-
tively, and the median survival times were 7.2 and 9.2
months, respectively. In the study by Clarke et al.,20 the main
grade 3/4 toxicities included neutropenia in 42% of patients,
cutaneous toxicity in 31% of patients, and asymptomatic
elevations in the hepatic biochemistry in 80% of patients.
Although the study by Clarke et al.20 showed that 600 mg/m2
could be safely administered, this conclusion was limited to
patients with a PS of 0 or 1. In the study by Rusthoven et al.,21
the main grade 3/4 toxicities included neutropenia in 39% of
patients, thrombocytopenia in 3% of patients, and skin rash in
39% of patients. On the basis of the toxicities seen during the
study by Rusthoven et al.21 and those seen in the study by
Cripps et al.,37 who used the same dosage and schedule in
patients with colorectal cancer, pemetrexed was reduced to
500 mg/m2. It is important to note, nevertheless, that neither
of these studies included vitamin supplementation.
Gemcitabine has been shown to be active and well
tolerated in large randomized NSCLC studies.8,38 The com-
bination of gemcitabine and pemetrexed has yielded encour-
aging results in several phase II trials.31,39,40 When adminis-
tered to 60 patients with advanced NSCLC, the combination
resulted in a 15.5% response rate and a median overall
survival time of 10.1 months. Reported toxicity incidences
were high, with grade 3 and 4 neutropenia in 61.7% (febrile
neutropenia in 15%), fatigue in 23.3%, and elevations of
aspartate aminotransferase and alanine aminotransferase in
15% and 20% of the patients, respectively; nevertheless,
vitamin supplementation was added only after the enrollment
of the first 13 patients.31 The other two phase II studies also
reported increased activity of the combination but with a poor
toxicity profile despite vitamin supplementation.39,40
We designed the present trial to administer pemetrexed
as a single agent or to administer pemetrexed and then
gemcitabine as sequential treatment. Theoretically, sequential
therapy allows the investigation of a single agent or a com-
bination of drugs after effective chemotherapy with standard
regimens but before the emergence of clinical drug resis-
tance. Additionally, sequential therapy may minimize the
potential for toxicity seen with concurrently administered
two-drug regimens while permitting full doses of each indi-
vidual drug. This could result in a potentially more effective
regimen with a lower toxicity profile than those seen in
combination treatment. Sequential administration has been
evaluated in both elderly and PS 2 patients using vinorelbine
and docetaxel.41 In 75 elderly patients with a PS of 0 or 1, the
sequential approach yielded encouraging results—a response
TABLE 4. Worst Grade 3/4 NCI-CTC Nonhematologic
Toxicity
Toxicity
No. of Patients (%)
Pem
(n  44)
Sequential
Pem/Gem
(n  43)
G3 G4 G3 G4
Fatigue 0 (0) 0 (0) 0 (0) 1 (2.3)
Rash 0 (0) 0 (0) 2 (4.7) 0 (0)
Allergic reaction 1 (2.3) 0 (0) 0 (0) 0 (0)
Pulmonary 2 (4.5) 0 (0) 0 (0) 0 (0)
Abdominal pain 0 (0) 0 (0) 0 (0) 1 (2.3)
Diarrhea 0 (0) 1 (2.3) 0 (0) 0 (0)
Mucositis 2 (4.5) 0 (0) 0 (0) 0 (0)
Melena 1 (2.3) 0 (0) 0 (0) 0 (0)
Anorexia 0 (0) 1 (2.3) 0 (0) 0 (0)
Edema 1 (2.3) 0 (0) 0 (0) 0 (0)
ALT 1 (2.3) 0 (0) 0 (0) 0 (0)
NCI-CTC, National Cancer Institute common toxicity criteria; Pem, pemetrexed;
pem/gem, pemetrexed/gemcitabine; G, grade; ALT, alanine aminotransferase.
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rate of 21% and a median survival time of 9 months—with
good tolerability.41
One possible limitation to our study is the high rate of
censoring for the TtPD analysis (15 patients with no objective
PD). Furthermore, the unexpectedly low TtPD and overall
survival results might be explained by the high percentage of
PS 2 patients in our study: 35.6%, 20.7% of whom were
younger than 70 years. Finally, although other studies often
group PS 2 and elderly patients together, which was typical at
the time our study was planned, elderly patients with good PS
tend to fare as well as younger patients with respect to
standard chemotherapy, whereas poor PS patients, regardless
of age, tend to have mostly palliative benefits.42–45 Because it
is well known that PS 0/1 and PS 2 patients constitute
different cohorts with different prognoses in advanced
NSCLC, we also examined efficacy by PS in our trial, and we
found that PS 0/1 patients performed better than PS 2 pa-
tients. This finding confirms that PS 2 is an important pre-
dictor of a poor outcome (shorter PFS and survival times).
Thus, dedicated PS 2–specific studies are needed along with
a better understanding of the reasons for compromised PS
(comorbidity, disease burden, or both) and of how these
factors affect treatment outcome.6,44
In conclusion, both single-agent pemetrexed (500 mg/m2)
and sequentially administered pemetrexed/gemcitabine (500
mg/m2 of pemetrexed and then 1200 mg/m2 of gemcitabine)
have shown moderate activity and are well-tolerated regi-
mens as first-line treatments of advanced NSCLC in elderly
patients (70 years of age) or in patients younger than 70
years who are unsuitable for platinum-based combination
chemotherapy (i.e., patients with a PS of 2). Although the
study was designed to identify which of these two treatment
modalities should be selected for further study, the results
suggest that either treatment is acceptable for further study in
a more homogeneous patient population such as PS 0/1
elderly or PS 2 adult patients.
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